...
首页> 外文期刊>International Journal of Pharmaceutical Sciences Review and Research >A VALIDATED HPTLC DETERMINATION OF AN ANGIOTENSIN RECEPTOR BLOCKER OLMESARTAN MEDOXOMIL FROM TABLET DOSAGE FORMby *Della Grace Thomas Parambi, Dr. Sr. Molly Mathew, Dr.V.Ganesan, Anila Jose, Dr. K. G. Revikumar, India. 007
【24h】

A VALIDATED HPTLC DETERMINATION OF AN ANGIOTENSIN RECEPTOR BLOCKER OLMESARTAN MEDOXOMIL FROM TABLET DOSAGE FORMby *Della Grace Thomas Parambi, Dr. Sr. Molly Mathew, Dr.V.Ganesan, Anila Jose, Dr. K. G. Revikumar, India. 007

机译:片剂剂量形式中有效的高效液相色谱法测定血管紧张素受体阻滞剂奥美沙坦MEDOXOMIL,作者:Della Grace Thomas Parambi博士,S。Molly Mathew博士,V.Ganesan博士,Anila Jose博士,K。G. Revikumar博士。 007

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The oral delivery of lipophilic drugs presents a major challenge because of the low aqueous solubility of such compounds. Self- microemulsifying drug delivery systems (SMEDDSs) have gained exposure for their ability to increase solubility and bioavailability of poorly soluble drugs. SMEDDS, which are isotropic mixtures of oils, surfactants, solvents and co-solvents/surfactants, can be used for the design of formulations in order to improve the oral absorption of highly lipophilic drug compounds. SMEDDS can be orally administered in soft or hard gelatin capsules and form fine relatively stable oil-in-water (o/w) emulsions upon aqueous dilution owing to the gentle agitation of the gastrointestinal fluids. The efficiency of oral absorption of the drug compound from the SMEDDS depends on many formulation?related parameters, such as surfactant concentra on, oil/surfactant ra o, polarity of the emulsion, droplet size and charge, all of which in essence determine the self-emulsification ability. Thus, only very specific pharmaceutical excipient combinations will lead to efficient self-microemulsifying systems. Although many studies have been carried out, there are few drug products on the pharmaceutical market formulated as SMEDDS confirming the difficulty of formulating hydrophobic drug compounds into such formulations. Significant improvement in the oral bioavailability of these drug compounds has been demonstrated for each case. The fact that almost 40% of the new drug compounds are hydrophobic in nature implies that studies with SMEDDS will continue, and more drug compounds formulated as SMEDDS will reach the pharmaceutical market in the future.
机译:亲脂性药物的口服递送面临着主要挑战,因为此类化合物的水溶性低。自微乳化药物递送系统(SMEDDS)由于具有增加难溶性药物的溶解度和生物利用度的能力而受到关注。 SMEDDS是油,表面活性剂,溶剂和助溶剂/表面活性剂的各向同性混合物,可用于配方设计,以改善高亲脂性药物化合物的口服吸收。 SMEDDS可以在软或硬明胶胶囊中口服给药,由于胃肠液的缓慢搅动,经水稀释后可形成相对稳定的细水包油型乳剂。从SMEDDS口服吸收药物化合物的效率取决于许多与制剂相关的参数,例如表面活性剂浓度,油/表面活性剂的比重,乳液的极性,液滴的大小和电荷,所有这些本质上决定了自我-乳化能力。因此,只有非常特殊的药物赋形剂组合才能产生有效的自微乳化系统。尽管已经进行了许多研究,但在制药市场上很少有药物配制为SMEDDS,这证实了将疏水性药物化合物配制到此类制剂中的困难。对于每种情况,已经证明这些药物化合物的口服生物利用度有显着改善。事实上,几乎40%的新药物化合物都是疏水性的,这意味着使用SMEDDS进行的研究将继续进行,并且将来有更多配制为SMEDDS的药物化合物将进入制药市场。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号